The grand opening took place on November 28, 2023 at the expanded facilities of the Kyowa Hakko Bio Yamaguchi Production Center, in Hofu City, Yamaguchi Prefecture, Japan.
Kyowa Hakko Bio president and CEO, Yuki Kanzaki addresses audience at grand opening event for the company's expanded manufacturing facility. Image courtesy of Kyowa Hakko Bio.
Kyowa Hakko Bio Co. Ltd. and Kyowa Hakko USA Inc., a subsidiary of Kirin Holdings Company Limited, has announced the grand opening of its expanded citicoline manufacturing facilities. The grand opening took place on November 28, 2023 at the expanded facilities of the Kyowa Hakko Bio Yamaguchi Production Center, in Hofu City, Yamaguchi Prefecture, Japan. According to the company’s press release, with the global aging population and rapid growth of the e-sports market, Kyowa Hakko Bio expects the demand for citicoline to surge, particularly in the U.S.
The expansion of its manufacturing facilities, says the company, will help meet the growing demand as well as establish a resilient global supply network that caters to pharmaceutical and health food manufacturers. At the grand opening event, the Kyowa Hakko Bio president and CEO, Yuki Kanzaki, emphasized the pivotal role its branded citicoline, Cognizin, would play in the company’s future success. The company also states that it is integrating citicoline into its upcoming product development initiative to further solidify Kyowa Hakko Bio’s commitment to health and wellness.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.